August 27th, 2014
Last year, Sentry provided support for a recently-published RAND report intended to clarify the 340B Program's purpose, value and extent. The report provides an insightful perspective on current utilization of the program and speculates on potential changes that may help shape the program's future.
August 25th, 2014
Sentry Data Systems announced today that they’re making available to pharmacies their industry-leading, proprietary 340B platform via a new offering called the Sentry 340B Technology Backbone.
August 7th, 2014
All hospitals with an active 340B ID as of July 1 are required to recertify to maintain their 340B eligibility. Failure to recertify annually will result in removal from the program.
July 28th, 2014
Last week, the Health Resources and Services Administration (HRSA) issued an interpretive rule clarifying their position that manufacturers should continue to extend 340B prices for orphan drugs when these drugs are purchased and used by free-standing cancer hospitals (CAN), sole community providers (SCH), rural referral centers (RRC) and critical access hospitals (CAH) for non-orphan indications.
July 18th, 2014
The first communication regarding HRSA’s third annual mandatory recertification process for participating 340B hospitals will be sent to the authorizing official for each hospital around Aug. 1.